Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Changes in the balance between pro-tumor and anti-tumor immune responses may impact the effectiveness of immunotherapy or other immune-based treatments targeting the tumor (Tumeh et al., 2014).”
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 2×
“Nanoparticles can be engineered to encapsulate chemotherapy agents and selectively deliver them to tumor sites, reducing systemic exposure and associated immune toxicity (Binnewies et al. 2018).”
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 1×
“…surveillance and anti-tumor activity within the tumor, potentially compromising the effectiveness of the immune response against cancer cells (Fridman et al., 2012) ...Chemotherapy drugs that have cytotoxic effects on rapidly dividing cells, including cancer cells, can inadvert-ently affect…”
Macrophage plasticity, polarization, and function in health and disease
Shapouri‐Moghaddam, A., Mohammadian, S., Vazini, H., Taghadosi, M., Esmaeili, S., Mardani, F., Seifi, B., Mohammadi, A., Afshari, J. T., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26429 · Cited by 4,930
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543 · cited 8×
“The rational combination of immunomodulatory agents with chemotherapy holds great promise for synergistically boosting the anti-tumor immune response (Mokhtari et al. 2017).”
InfluentialImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 1×
“While research in this area is ongoing, several biomarkers show promise in predicting chemotherapy-induced immune suppression (Havel et al. 2019).”
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · cited 1×
“The impaired activation and function of TILs caused by chemotherapy can result in decreased cytotoxicity, reduced cytokine production, and compromised immune surveillance within the tumor microenvironment (Restifo et al. 2012).”
T follicular helper cell biology: a decade of discovery and diseases
Crotty, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.011 · Cited by 1,591
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · cited 1×
“The immune system consists of a complex network of cells, tissues, and molecules that work together to recognize and eliminate foreign or abnormal cells, including cancer cells (Casares et al., 2005).”
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 2×
“Investigating the immune evasion mechanisms employed by cancer cells in response to chemotherapy can shed light on potential therapeutic targets for overcoming treatment resistance (Ruffell & Coussens, 2015).”
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404 · cited 2×
“The emerging field of immuno-therapy, including immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines, has revolutionized cancer treatment by leveraging the immune system's inherent anti-tumor capabilities (Wang et al. 2017).”
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652 · cited 1×
“(Seruga et al., 2008) Epithelial Barrier Dysfunction Chemotherapy can disrupt the integrity of the epithelial barrier, making it easier for pathogens to enter the body and cause infections.”
Immune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437 · cited 1×
“For example, some chemotherapeutic agents may induce apoptosis or inhibit the proliferation of T-lymphocytes, which are essential for orchestrating immune responses against cancer cells (Gajewski et al. 2006).”
Schraml, B. U., & Reis e Sousa, C. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.11.001 · Cited by 197
Tu, L., Guan, R., Yang, H., Zhou, Y., Hong, W., Ma, L., Zhao, G., & Yu, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.32785 · Cited by 167 · cited 1×
“(Tu et al. 2020) Upregulation of immune checkpoint molecules may indicate immune exhaustion and compromised anti-tumor immune responses.”
Cited by
Mafe, A. N., & Büsselberg, D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070820 · Cited by 18
Metadata
- Authors
- Sharma, A., Jasrotia, S., & Kumar, A.
- Venue
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Published
- 2023-10-31
- Volume
- 397
- Issue
- 5
- Pages
- 2551-2566
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W4388046483
- Cited by
- 174
- References
- 22
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.